ANTABIO Raises €25 Million in Series B Financing
The financing will be used to support the clinical development of a next generation antibacterial combination
14-Dec-2023 -
Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant bacterial infections, announced that it has raised €25m in a series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from the company’s historical investors ...
Acinetobacter baumannii
antimicrobial resistance
bacterial infections
+3